^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    KAT6 inhibitor

    Related drugs:
    2ms
    A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144 (clinicaltrials.gov)
    P1, N=12, Recruiting, Pfizer
    New P1 trial
    |
    prifetrastat (PF-07248144)
    2ms
    A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=240, Recruiting, Stemline Therapeutics, Inc. | N=124 --> 240
    Enrollment change • First-in-human
    |
    Orserdu (elacestrant) • MEN2312
    3ms
    Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=160, Recruiting, Olema Pharmaceuticals, Inc. | N=90 --> 160
    Enrollment change • First-in-human
    |
    fulvestrant
    4ms
    C4551001: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=320, Recruiting, Pfizer | Trial completion date: Jan 2028 --> Sep 2029
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • vepdegestrant (ARV-471) • atirmociclib (PF-07220060) • prifetrastat (PF-07248144)
    4ms
    A Study of KC1086 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=66, Not yet recruiting, Beijing Konruns Pharmaceutical Co., Ltd.
    New P1 trial
    4ms
    A Study to Learn About How Different Forms of Study Medicine PF-07248144 Are Taken Up Into the Blood in Healthy Adults (clinicaltrials.gov)
    P1, N=24, Completed, Pfizer
    New P1 trial
    |
    prifetrastat (PF-07248144)
    4ms
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. (clinicaltrials.gov)
    P3, N=400, Recruiting, Pfizer | Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2027 --> Jul 2027
    Enrollment open • Trial primary completion date
    |
    everolimus • fulvestrant • exemestane • prifetrastat (PF-07248144)
    5ms
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Pfizer
    New P3 trial
    |
    everolimus • fulvestrant • exemestane • prifetrastat (PF-07248144)
    5ms
    An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Fudan University
    New P2 trial
    |
    AiRuiLi (adebrelimab) • HRS-2189
    6ms
    C4551001: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=320, Recruiting, Pfizer | N=186 --> 320 | Trial completion date: Mar 2027 --> Jan 2028 | Trial primary completion date: Aug 2025 --> Jan 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • vepdegestrant (ARV-471) • atirmociclib (PF-07220060) • prifetrastat (PF-07248144)
    10ms
    C4551001: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=186, Recruiting, Pfizer | Trial completion date: Nov 2026 --> Mar 2027 | Trial primary completion date: May 2025 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • atirmociclib (PF-07220060) • prifetrastat (PF-07248144)
    11ms
    Study of OP-3136 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=90, Recruiting, Olema Pharmaceuticals, Inc.
    New P1 trial